{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-004158","form_type":"8-K","ticker":"IXHL","cik":"0001873875","company_name":"Incannex Healthcare Inc.","filed_at":"2026-01-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.632813+00:00","generated_at":"2026-05-16T10:26:22.106989+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Incannex reports >$70M cash, two positive Phase 2 readouts, FDA Fast Track; outlines 2026 outlook","bullets":["Cash and cash equivalents >$70M, providing operating runway into 2027.","IHL-42X (OSA) Phase 2 RePOSA: up to 83% AHI reduction; FDA Fast Track designation.","PSX-001 (GAD) Phase 2: statistically significant improvement on HAM-A vs placebo.","Completed $12.5M private placement; eliminated all Series A warrants.","Authorized $20M share repurchase program."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-004158","json":"https://secwatch.observer/filing/0001213900-26-004158.json","markdown":"https://secwatch.observer/filing/0001213900-26-004158.md","text":"https://secwatch.observer/filing/0001213900-26-004158.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1873875/000121390026004158/0001213900-26-004158-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1873875/000121390026004158/ea0272883-8k_incannex.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T10:26:22.106989+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}